Author:incardatheraadmin

November 7, 2022 In News, Press Releases

Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions

Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial Fibrillation Topline Results from the Ongoing Pivotal Phase 3 RESTORE-1 Trial of InRhythm Expected in Early 2024 SAN FRANCISCO, Nov. 07, 2022 (GLOBE...

September 7, 2022 In Events, News

InCarda Presents Additional Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 European Society of Cardiology Congress in Barcelona

Phase 2 INSTANT study results demonstrate conversion with inhaled flecainide leads to rapid reduction in ventricular rate and alleviation of atrial fibrillation-related symptoms; the study also demonstrates the potential to reduce healthcare costs related to acute episodes of atrial fibrillation   [caption id="attachment_23407" align="aligncenter" width="1782"] Dr. John...

July 26, 2022 In News, Press Releases

InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation

Single Pivotal Phase 3 Trial to Support Filing of New Drug Application Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pick” in Circulation: Arrhythmia and Electrophysiology SAN FRANCISCO, CA – July 26, 2022 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company...

May 2, 2022 In Events, News

InCarda Presents Phase 2 Safety and Efficacy Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Heart Rhythm Society Conference in San Francisco

[caption id="attachment_23373" align="aligncenter" width="800"] Dr. Chris Dufton, SVP of Clinical Development, answering questions about INSTANT P2 at HRS 2022 in San Francisco.[/caption] Phase 2 INSTANT study results demonstrate rapid and reproducible restoration of normal heart rhythm with symptom resolution and a predictable and favorable safety profile...

April 6, 2022 In News

InCarda Therapeutics Announces Publication of Phase 2 Data Demonstrating Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm Is Safe and Effective

The original article titled “Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm” published in the peer-reviewed journal, Circulation: Arrhythmia and Electrophysiology San Francisco, California, March 15, 2022 – InCarda Therapeutics, Inc. (InCarda) announces that...

April 6, 2022 In Publications

Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm

Harry J.G.M. Crijns, Arif Elvan, Nadea Al-Windy, Ype S. Tuininga, Erik Badings, Ismail Aksoy, Isabelle C. Van Gelder, Prashanti Madhavapeddi, A. John Camm, Peter R. Kowey, Jeremy N. Ruskin, Luiz Belardinelli and the INSTANT Investigators* Originally published 24 Feb 2022 https://doi.org/10.1161/CIRCEP.121.010204Circulation: Arrhythmia and Electrophysiology. 2022;15   Click here...

January 26, 2022 In Events, News

InCarda Presents Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Atrial Fibrillation Symposium in New York

Phase 2 INSTANT study results demonstrate rapid restoration of normal heart rhythm with a predictable and favorable safety profile for orally inhaled flecainide.   [caption id="attachment_23370" align="aligncenter" width="800"] Meisa Propst, VP of Clinical Operations at InCarda, presented the P2 INSTANT Safety Analysis Poster at the 2022 AF...